Baseline characteristics at the time of diagnosis grouped, according to PCPI
| Variable . | Entire cohort . | High PCPI . | Low PCPI . | P . |
|---|---|---|---|---|
| Patients, n (%) | 306 | 79 (26) | 227 (74) | |
| Median age , y | 66 | 69 | 64 | .008 |
| Age >65 y, n (%) | 159 (52) | 52 (66) | 107 (47) | .006 |
| Sex, male (%) | 186 (61) | 47 (59) | 139 (61) | .79 |
| Median hemoglobin, g/dL | 12.7 | 12.5 | 12.7 | .04 |
| Median β2 microglobulin, μg/mL | 2.5 | 2.9 | 2.4 | .03 |
| Median serum albumin, g/dL | 3.6 | 3.5 | 3.7 | .05 |
| Abnormal LDH, U/L, % | 16/227 (7) | 5/59 (8) | 11/168 (7) | .56 |
| Median creatinine, mg/dL | 1.1 | 1 | 1.1 | .19 |
| Bone marrow evaluation | ||||
| Median bone marrow plasma cells, % | 20 | 20 | 20 | .10 |
| BM plasma cells >20 (%) | 115 (38) | 38 (48) | 77 (34) | .03 |
| BM plasma cells ≤20 (%) | 191 (62) | 41 (52) | 150 (66) | |
| BM plasma cells ≥10 (%) | 302 (99) | 77 (97) | 225 (99) | .27 |
| BM plasma cells <10 (%) | 4 (1) | 2 (3) | 2 (1) | |
| FLC ratio (involved/uninvolved) ≥8 (%) | 123/260 (47) | 36/71 (51) | 87/189 (46) | .58 |
| Involved light chains (%) | .49 | |||
| κ | 196 (64) | 48 (61) | 148 (66) | |
| λ | 108 (36) | 31 (39) | 77 (34) | |
| Serum monoclonal protein | ||||
| Median M-spike, g/dL | 2.1 | 1.9 | 2.1 | .06 |
| ≥3 (%) | 62 (20) | 12/79 (17) | 50/226 (22) | .26 |
| <3 (%) | 243 (80) | 67/79 (83) | 176/226 (78) | |
| >2 (%) | 156 (51) | 33 (42) | 123 (54) | |
| ≤2 (%) | 149 (49) | 46 (58) | 103 (46) | |
| Median light chain concentration, mg/dL | ||||
| κ | 2.5 | 2.8 | 2.4 | .76 |
| λ | 1.2 | 1.3 | 1.2 | .14 |
| Ig heavy chain, mg/dL (%) | ||||
| IgG | 234 (76) | 58 (73) | 176 (78) | .45 |
| IgA | 57 (19) | 18 (23) | 39 (17) | .31 |
| IgM | 3 (1) | 0 (0) | 3 (1) | .57 |
| IgD | 2 (1) | 2 (3) | 0 (0) | .07 |
| Light chains only and others (%) | 10 (3) | 1 (1) | 9 (4) | .46 |
| Variable . | Entire cohort . | High PCPI . | Low PCPI . | P . |
|---|---|---|---|---|
| Patients, n (%) | 306 | 79 (26) | 227 (74) | |
| Median age , y | 66 | 69 | 64 | .008 |
| Age >65 y, n (%) | 159 (52) | 52 (66) | 107 (47) | .006 |
| Sex, male (%) | 186 (61) | 47 (59) | 139 (61) | .79 |
| Median hemoglobin, g/dL | 12.7 | 12.5 | 12.7 | .04 |
| Median β2 microglobulin, μg/mL | 2.5 | 2.9 | 2.4 | .03 |
| Median serum albumin, g/dL | 3.6 | 3.5 | 3.7 | .05 |
| Abnormal LDH, U/L, % | 16/227 (7) | 5/59 (8) | 11/168 (7) | .56 |
| Median creatinine, mg/dL | 1.1 | 1 | 1.1 | .19 |
| Bone marrow evaluation | ||||
| Median bone marrow plasma cells, % | 20 | 20 | 20 | .10 |
| BM plasma cells >20 (%) | 115 (38) | 38 (48) | 77 (34) | .03 |
| BM plasma cells ≤20 (%) | 191 (62) | 41 (52) | 150 (66) | |
| BM plasma cells ≥10 (%) | 302 (99) | 77 (97) | 225 (99) | .27 |
| BM plasma cells <10 (%) | 4 (1) | 2 (3) | 2 (1) | |
| FLC ratio (involved/uninvolved) ≥8 (%) | 123/260 (47) | 36/71 (51) | 87/189 (46) | .58 |
| Involved light chains (%) | .49 | |||
| κ | 196 (64) | 48 (61) | 148 (66) | |
| λ | 108 (36) | 31 (39) | 77 (34) | |
| Serum monoclonal protein | ||||
| Median M-spike, g/dL | 2.1 | 1.9 | 2.1 | .06 |
| ≥3 (%) | 62 (20) | 12/79 (17) | 50/226 (22) | .26 |
| <3 (%) | 243 (80) | 67/79 (83) | 176/226 (78) | |
| >2 (%) | 156 (51) | 33 (42) | 123 (54) | |
| ≤2 (%) | 149 (49) | 46 (58) | 103 (46) | |
| Median light chain concentration, mg/dL | ||||
| κ | 2.5 | 2.8 | 2.4 | .76 |
| λ | 1.2 | 1.3 | 1.2 | .14 |
| Ig heavy chain, mg/dL (%) | ||||
| IgG | 234 (76) | 58 (73) | 176 (78) | .45 |
| IgA | 57 (19) | 18 (23) | 39 (17) | .31 |
| IgM | 3 (1) | 0 (0) | 3 (1) | .57 |
| IgD | 2 (1) | 2 (3) | 0 (0) | .07 |
| Light chains only and others (%) | 10 (3) | 1 (1) | 9 (4) | .46 |
LDH, lactate dehydrogenase.